[Treatment of Sialorrhea with Botulinum Neurotoxin Type A - Consensus Practice Recommendations for Children and Adults]. / Behandlung der Sialorrhoe mit Botulinum Neurotoxin Typ A Konsentierte Praxisempfehlungen für Kinder und Erwachsene.
Fortschr Neurol Psychiatr
; 90(5): 212-221, 2022 May.
Article
en De
| MEDLINE
| ID: mdl-35453158
Sialorrhea, uncontrolled, excessive drooling, accompanies different, mostly neurological disorders from childhood to adulthood. With incobotulinumtoxinA (Xeomin, IncoBoNT/A, Merz Pharmaceuticals GmbH), an approved medication for the treatment of sialorrhea has been available since 2019. Patient selection, possible therapy goals, treatment and the management of specific treatment situations build the focus of this interdisciplinary expert consensus recommendations with the intent to facilitate access to treatment and to contribute to qualified botulinum toxin therapy.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Sialorrea
/
Toxinas Botulínicas Tipo A
/
Enfermedades del Sistema Nervioso
Tipo de estudio:
Guideline
Límite:
Adolescent
/
Adult
/
Child
/
Humans
Idioma:
De
Revista:
Fortschr Neurol Psychiatr
Año:
2022
Tipo del documento:
Article
País de afiliación:
Alemania